RNXT: 57% | RenovoRx Announces New Positive Interim Phase III Data Demonstrating RenovoGem™ Delays Cancer Progression by Eight Months in Locally Advanced Pancreatic Cancer
JOBY: 21.5% | Joby Welcomes $100 Million Investment as It Expands Partnership With SK Telecom
KTRA: 54% | Kintara Therapeutics Awarded $2.0 Million National Institutes of Health SBIR Grant to Support the Clinical Development of REM-001
